(Q37933370)

25 August 2017

1 reference

title

Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum (English)

1 reference

25 August 2017

main subject

Pseudomonas aeruginosa

0 references

author name string

Kristi A Traugott

1

1 reference

25 August 2017

Kelly Echevarria

2

1 reference

25 August 2017

Pamela Maxwell

3

1 reference

25 August 2017

Kay Green

4

1 reference

25 August 2017

James S Lewis

5

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 June 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

31

1 reference

25 August 2017

issue

6

1 reference

25 August 2017

page(s)

598-608

1 reference

Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Pseudomonas aeruginosa bloodstream infections: how should we treat them?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Overview of nosocomial infections caused by gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Pseudomonas bacteremia. Review of 108 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Combination therapy as a tool to prevent emergence of bacterial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Antibiotic resistance in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Identification of optimal combinations for empirical dual antimicrobial therapy of Pseudomonas aeruginosa infection: potential role of a Combination Antibiogram

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Efficacy of monotherapy in the treatment of Pseudomonas ventilator-associated pneumonia in patients with trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Ventilator-associated pneumonia due to Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Combination therapy versus monotherapy: a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia [ISRCTN31976779].

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy*

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.6.598

21 January 2018

Identifiers

DOI

10.1592/PHCO.31.6.598

1 reference

25 August 2017

1 reference